Aeterna Zentaris Inc. (Nasdaq: AEZS) completed the clinical phase of its Phase 3 clinical study of Zoptrex. Shares of the specialty biopharmaceutical climbed 55 cents to close at $3.15.
Aeterna Zentaris completes clinical phase
January 31, 2017 at 16:13 PM EST
